Hiding in Plain Sight: The Neuro-Protective Benefit of Tropomyosin Receptor Kinase Inhibition in Non–Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers

The triad of neurotrophic receptor tyrosine kinase (NTRK) receptors, Trk-A, B, and C (NTRK1,2, and 3 genes), is associated with multiple normal neurologic functions, including pain sensation, appetite regulation, proprioception, memory, and learning.1 Larotrectinib is a stand-alone licensed Tropomyosin Receptor Kinase (TRK) inhibitor for NTRK-rearranged cancers.2 In addition, several next-generation ALK and ROS1 tyrosine kinase inhibitors are also either licensed as TRK inhibitors for the treatment of NTRK-rearranged cancers (entrectinib, repotrectinib) or have noticeable off-target anti–TRK-related activity or side effects (taletrectinib, lorlatinib).